The phase I/II trial (NCT04214860) evaluating frontline APR-246 combined with AZA and VEN in TP53-mutated AML met its primary efficacy endpoint, demonstrating a CR/CRi rate of 53% (CR 37%) in preliminary results [40]. This evidence concerns the gene TP53 and acute myeloid leukemia.